Technical Analysis for PMCB - PharmaCyte Biotech, Inc.

Grade Last Price % Change Price Change
D 3.3 -2.65% -0.09
PMCB closed down 2.65 percent on Friday, September 24, 2021, on 9 percent of normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong N/A N/A Down
Historical PMCB trend table...

Date Alert Name Type % Chg
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
Spinning Top Other -2.65%
Narrow Range Bar Range Contraction -2.65%
NR7 Range Contraction -2.65%
Inside Day Range Contraction -2.65%
Fell Below 20 DMA Bearish -2.37%
Narrow Range Bar Range Contraction -2.37%
Crossed Above 20 DMA Bullish -4.90%
Narrow Range Bar Range Contraction -4.90%
Older End-of-Day Signals for PMCB ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
10 DMA Resistance about 15 hours ago
Down 3% about 15 hours ago
Fell Below Previous Day's Low about 15 hours ago
Down 2 % about 15 hours ago
Down 1% about 15 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


PharmaCyte Biotech, Inc. Description

PharmaCyte Biotech, Inc., a clinical stage biotechnology company, focuses on developing and commercializing cellular therapies for cancer and diabetes in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable non-metastatic pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the activation of cancer-killing drugs to the source of the cancer. It is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes; and therapies for cancer based on the constituents of the cannabis plant. PharmaCyte Biotech, Inc. has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and a research agreement with the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was founded in 1996 and is based in Laguna Hills, California.


Sector: Healthcare
Industry: Biotechnology

Is PMCB a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 9.98
52 Week Low 2.25
Average Volume 13,002,881
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 3.43
10-Day Moving Average 3.39
Average True Range 0.56
ADX 34.8
+DI 35.12
-DI 16.97
Chandelier Exit (Long, 3 ATRs) 2.42
Chandelier Exit (Short, 3 ATRs) 4.81
Upper Bollinger Bands 3.74
Lower Bollinger Band 3.12
Percent B (%b) 0.29
BandWidth 17.82
MACD Line -0.09
MACD Signal Line -0.10
MACD Histogram 0.0024
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.48
Resistance 3 (R3) 3.49 3.45 3.45
Resistance 2 (R2) 3.45 3.40 3.44 3.44
Resistance 1 (R1) 3.37 3.37 3.35 3.36 3.43
Pivot Point 3.33 3.33 3.32 3.32 3.33
Support 1 (S1) 3.25 3.28 3.23 3.24 3.17
Support 2 (S2) 3.21 3.25 3.20 3.16
Support 3 (S3) 3.13 3.21 3.15
Support 4 (S4) 3.12